{"id":"oral-tab-tacrolimus","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"20-40","effect":"Hypertension"},{"rate":"15-30","effect":"Hyperglycemia"},{"rate":"5-15","effect":"Tremor"},{"rate":"10-20","effect":"Headache"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"1-5","effect":"Neurotoxicity (encephalopathy)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin phosphatase activity. By blocking calcineurin, it prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), which is essential for IL-2 and other cytokine gene transcription. This results in potent immunosuppression, making it effective for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby preventing the transcription of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:26.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune conditions (off-label use in various settings)"}]},"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT05622318","phase":"PHASE2","title":"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-08-29","conditions":"Graft-versus-host Disease","enrollment":56},{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT05242315","phase":"PHASE4","title":"Extended-Release Tacrolimus Following Liver Transplantation","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-05-15","conditions":"Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction","enrollment":94},{"nctId":"NCT06900777","phase":"NA","title":"Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-04-01","conditions":"Vitiligo, Child, Progressive Disease","enrollment":90},{"nctId":"NCT04720326","phase":"PHASE4","title":"Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Geissler","startDate":"2020-12-23","conditions":"Prophylaxis Against Liver Transplant Rejection","enrollment":268},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT05744635","phase":"","title":"Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2023-05-10","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT03511560","phase":"PHASE4","title":"Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-07-26","conditions":"Renal Transplant Rejection, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT03794492","phase":"PHASE4","title":"Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-03-31","conditions":"Kidney Transplant","enrollment":169},{"nctId":"NCT06268769","phase":"PHASE4","title":"Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs","status":"RECRUITING","sponsor":"Edward Geissler","startDate":"2024-03-09","conditions":"Immunosuppression","enrollment":300},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT04420195","phase":"PHASE2","title":"Envarsus XR in Lung Transplant","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-10-23","conditions":"Lung Transplant","enrollment":41},{"nctId":"NCT05089604","phase":"PHASE4","title":"Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-01-09","conditions":"Liver Transplantation, Immunosuppression, Neurotoxicity","enrollment":124},{"nctId":"NCT04496401","phase":"PHASE4","title":"PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2020-09-28","conditions":"Kidney Transplantation, Pancreas Transplantation, Diabetes","enrollment":25},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT04048161","phase":"PHASE4","title":"Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome","status":"COMPLETED","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2019-11-12","conditions":"Nephrotic Syndrome in Children","enrollment":270},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT03864926","phase":"PHASE4","title":"Envarsus in Delayed Graft Function (E-DGF)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-03-18","conditions":"Delayed Graft Function","enrollment":100},{"nctId":"NCT03713645","phase":"PHASE4","title":"Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Temple University","startDate":"2018-11-12","conditions":"Kidney Transplant","enrollment":36},{"nctId":"NCT03289650","phase":"PHASE3","title":"Extended Release Tacrolimus vs. Twice-Daily Tacrolimus","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2017-09-05","conditions":"End Stage Renal Disease, Rejection of Renal Transplant","enrollment":29},{"nctId":"NCT05202145","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT04080076","phase":"PHASE4","title":"Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy","status":"WITHDRAWN","sponsor":"NephroNet, Inc.","startDate":"2019-01-12","conditions":"Renal Disease","enrollment":""},{"nctId":"NCT05353010","phase":"PHASE1","title":"A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2022-05-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT03099122","phase":"PHASE4","title":"A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-16","conditions":"End-stage Renal Disease","enrollment":115},{"nctId":"NCT04973982","phase":"NA","title":"ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT","status":"WITHDRAWN","sponsor":"Barts & The London NHS Trust","startDate":"2022-01-31","conditions":"Renal Transplant Failure","enrollment":""},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT05109390","phase":"PHASE1","title":"A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-27","conditions":"Healthy","enrollment":72},{"nctId":"NCT04867720","phase":"PHASE4","title":"Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-03-16","conditions":"Liver Transplant","enrollment":112},{"nctId":"NCT03828058","phase":"PHASE2","title":"Envarsus XL Immunosuppression Following Liver Transplantation","status":"COMPLETED","sponsor":"Methodist Healthcare","startDate":"2019-04-01","conditions":"Recipients of Liver Transplant","enrollment":110},{"nctId":"NCT01820572","phase":"PHASE3","title":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-27","conditions":"Kidney Transplantation","enrollment":446},{"nctId":"NCT04633733","phase":"PHASE1","title":"The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-08-22","conditions":"Healthy Male Volunteers","enrollment":24},{"nctId":"NCT00713284","phase":"PHASE4","title":"Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2007-05","conditions":"Renal Transplantation","enrollment":29},{"nctId":"NCT03380936","phase":"EARLY_PHASE1","title":"Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2018-01-17","conditions":"Kidney Transplant Rejection","enrollment":4},{"nctId":"NCT02954159","phase":"PHASE3","title":"Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-05-18","conditions":"Ulcerative Colitis","enrollment":4},{"nctId":"NCT02500212","phase":"PHASE4","title":"Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-07","conditions":"Organ or Tissue Transplant; Complications","enrollment":75},{"nctId":"NCT03828682","phase":"PHASE4","title":"Veloxis de Novo Kidney Transplant ECSWD","status":"UNKNOWN","sponsor":"Simon Tremblay, PharmD, PhD","startDate":"2019-06-21","conditions":"Kidney Transplantation, Immunosuppression","enrollment":60},{"nctId":"NCT04102943","phase":"PHASE4","title":"Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-11-30","conditions":"Kidney Transplant","enrollment":128},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT01938625","phase":"PHASE2","title":"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-12-12","conditions":"Hepatitis C, Chronic","enrollment":35},{"nctId":"NCT00078559","phase":"PHASE1, PHASE2","title":"Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Kidney Transplantation, Kidney Disease","enrollment":10},{"nctId":"NCT02432833","phase":"PHASE4","title":"Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"End Stage Renal Disease","enrollment":428},{"nctId":"NCT02373202","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-02","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT02438982","phase":"PHASE3","title":"Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome","status":"COMPLETED","sponsor":"Nilratan Sircar Medical College","startDate":"2015-05-08","conditions":"Nephrotic Syndrome","enrollment":120},{"nctId":"NCT00596947","phase":"PHASE4","title":"Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2005-10","conditions":"Transplants and Implants","enrollment":18},{"nctId":"NCT03062813","phase":"PHASE4","title":"Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-02-01","conditions":"Hepatitis B Virus Associated Nephrotic Syndrome","enrollment":112},{"nctId":"NCT00402168","phase":"PHASE2","title":"A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-01","conditions":"Renal Transplant","enrollment":173},{"nctId":"NCT00240994","phase":"PHASE2","title":"Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression","enrollment":35},{"nctId":"NCT00087581","phase":"PHASE4","title":"Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Kidney Transplantation","enrollment":720},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543},{"nctId":"NCT00817206","phase":"PHASE3","title":"Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-12","conditions":"Renal Failure","enrollment":326},{"nctId":"NCT00608244","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-11","conditions":"Liver Failure","enrollment":59},{"nctId":"NCT01842269","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-01","conditions":"Kidney Transplantation","enrollment":156},{"nctId":"NCT00496483","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT00772148","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-10","conditions":"Liver Failure","enrollment":58},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT00765661","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Failure, Renal Failure","enrollment":63},{"nctId":"NCT02446431","phase":"EARLY_PHASE1","title":"Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","status":"RECRUITING","sponsor":"Miller Children's & Women's Hospital Long Beach","startDate":"2014-07","conditions":"Solid Tumor","enrollment":20},{"nctId":"NCT01342016","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2011-04","conditions":"Lupus Nephritis","enrollment":84},{"nctId":"NCT00895583","phase":"PHASE4","title":"Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Graft Rejection, Kidney Transplant, Renal Allograft Recipients","enrollment":254},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00005113","phase":"PHASE3","title":"A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"1999-07","conditions":"End-Stage Renal Disease, Kidney Transplantation","enrollment":102},{"nctId":"NCT00400400","phase":"PHASE4","title":"Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":400},{"nctId":"NCT00369382","phase":"PHASE4","title":"Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-09","conditions":"Graft Rejection, Kidney Failure","enrollment":121},{"nctId":"NCT01038167","phase":"PHASE1","title":"A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-01","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT00166842","phase":"PHASE4","title":"Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2002-09","conditions":"Transplantation, Kidney Transplantation, Immunosuppression","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral Tab Tacrolimus","genericName":"Oral Tab Tacrolimus","companyName":"NephroNet, Inc.","companyId":"nephronet-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby preventing the transcription of pro-inflammatory cytokines. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Atopic dermatitis, Autoimmune conditions (off-label use in various settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}